Management of Suspected Giant Cell Arteritis with Hypertension and CAD History

Initial Assessment and Diagnosis

The American College of Rheumatology recommends that patients with suspected giant cell arteritis (GCA) presenting with hypertension and coronary artery disease (CAD) history should be referred to a specialist team for multidisciplinary diagnostic work-up and management 1
Temporal artery biopsy should be performed within 2 weeks of starting glucocorticoid therapy to confirm the diagnosis, as recommended by the American College of Rheumatology 3, 4
Noninvasive vascular imaging (ultrasound, CT, PET-CT, or MRI) should be obtained to evaluate large vessel involvement, according to the American College of Rheumatology 5, 4
Laboratory assessment should include inflammatory markers (ESR, CRP) as normal values should raise suspicion for alternative diagnoses, as stated by the European League Against Rheumatism 6

The American College of Rheumatology recommends starting high-dose oral glucocorticoids (40-60 mg/day prednisone-equivalent) immediately in patients with suspected GCA, even in those with hypertension and CAD history 1, 2
Daily dosing is preferred over alternate-day scheduling, according to the American College of Rheumatology 2, 7
Consider adding aspirin in patients with critical or flow-limiting involvement of vertebral or carotid arteries, as recommended by the American Heart Association 7

Monitor blood pressure closely during high-dose glucocorticoid therapy as it may worsen hypertension, according to the American College of Cardiology 1
Consider adding a glucocorticoid-sparing agent (tocilizumab or methotrexate) to reduce cumulative steroid exposure in patients with CAD and hypertension, as recommended by the American College of Rheumatology 2, 5

Once disease is controlled, taper glucocorticoid dose to 15-20 mg/day within 2-3 months, according to the American College of Rheumatology 1
After 1 year, aim for ≤5 mg/day, as recommended by the American College of Rheumatology 1
Monitor for disease relapse during tapering using clinical assessment and inflammatory markers, according to the European League Against Rheumatism 8

Consider tocilizumab (162 mg subcutaneously weekly) as a glucocorticoid-sparing agent, particularly in patients with cardiovascular risk factors, as recommended by the American College of Rheumatology 2
Provide bone protection therapy (calcium, vitamin D) to prevent osteoporosis, according to the National Osteoporosis Foundation 6

Regular monitoring of blood pressure and cardiovascular status is recommended, according to the American College of Cardiology 1
Periodic assessment of inflammatory markers (ESR, CRP) is necessary, as stated by the American College of Rheumatology 1, 2
Monitor for glucocorticoid-related adverse effects, which occur in up to 86% of patients, according to the European League Against Rheumatism 6